Lacerta Therapeutics

Lacerta Therapeutics is a clinical-stage gene therapy company based in Alachua, Florida, founded in 2017. The company specializes in developing treatments for central nervous system (CNS) and lysosomal storage diseases using proprietary adeno-associated virus (AAV) vector technologies. Lacerta utilizes a scalable vector manufacturing platform and capsid variants to target genetic disorders at the molecular level.

The company's pipeline includes preclinical programs focused on gene therapies for Mucopolysaccharidosis III and Friedreich Ataxia. These therapies aim to address the underlying genetic causes of CNS and lysosomal storage disorders through innovative gene transference methods. Lacerta holds a patent related to autosomal recessive disorders, genetics, and molecular biology. The company has collaborated with partners such as Sarepta and the University of Florida in its research efforts.